The predictive value of peripheral blood monocytic myeloid-derived suppressor cells for survival and immunotherapy responses in tumor patients
Peripheral blood M-MDSCs may be used to predict overall survival and immunotherapy efficacy outcomes. This study provides a putative predictive biomarker for clinicians to choose from to predict tumor patients' survival and the selection of receiving immunotherapy regimens.
Authors
- Yan Ding (ORCID: https://orcid.org/0000-0002-4269-9476)
- Jing Hu (ORCID: https://orcid.org/0000-0002-1184-3236)
- Xiao Yuan (ORCID: https://orcid.org/0009-0004-9805-349X)
- Yuting Su (ORCID: https://orcid.org/0000-0001-5165-204X)
- Wanying Sheng
- Lu Wang (ORCID: https://orcid.org/0000-0003-2525-4966)
- Xu Wang (ORCID: https://orcid.org/0000-0003-1094-1843)
- Deqiang Wang (ORCID: https://orcid.org/0000-0002-8411-312X)
- Chunhua Dai (ORCID: https://orcid.org/0000-0003-0377-1735)
- Minjie Guo
Institutions
- Jiangsu University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- BMC Immunology
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1186/s12865-025-00722-7
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00